Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.8 SEK | +1.54% | +3.12% | +28.07% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
62.09M | - | |||||
74.45B | ||||||
9.18B | ||||||
5.03B | - | - | ||||
5.02B | ||||||
3.82B |
- Stock Market
- Equities
- ORX Stock
- Charts Orexo AB
- Sector Chart